Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIP152 + pembrolizumab
- Development stage
- Preclinical
- Lead developer
- Vincerx
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
VIP152 + pembrolizumab is an experimental combination therapy of two distinct drugs: **VIP152 (also known as enitociclib or BAY-1251152)** and **pembrolizumab (Keytruda)**. - **VIP152** is a selective small molecule inhibitor of cyclin-dependent kinase 9 (CDK9), a regulator of transcription and cancer cell survival. By inhibiting CDK9, VIP152 reduces the transcription of anti-apoptotic and oncogenic genes, potentially leading to cancer cell death. - **Pembrolizumab** is a humanized monoclonal antibody targeting the programmed cell death protein 1 (**PD-1**) receptor, functioning as an immune checkpoint inhibitor to enhance anti-tumor immunity. This combination is under clinical investigation for various cancers, especially **hematologic malignancies and solid tumors**, with the rationale that CDK9 inhibition can sensitize tumors to immune checkpoint blockade.
- Brand names
- Keytruda
- Other names
- enitociclib + pembrolizumab
02
Targets
CDK9 (Cyclin-dependent kinase 9)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on VIP152 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIP152 + pembrolizumab.